Superiority of ApoB/ApoA1 ratio for predicting cardiovascular risk in pooled analyses of the incremental decrease in endpoints through aggressive lipid-lowering (IDEAL) and treating to new targets (TNT) trials

被引：0
|
作者：
Kastelein, John J.
Holme, Ingar
Barter, Philip
Olsson, Anders G.
Cater, Nilo B.
DeMicco, David A.
Gaffney, Michael
Szarek, Michael
LaRosa, John C.
Pedersen, Terje R.
机构：
[1] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[2] Ullevaal Univ Hosp, Oslo, Norway
[3] Heart Res Inst, Sydney, NSW, Australia
[4] Linkoping Univ Hosp, S-58185 Linkoping, Sweden
[5] Pfizer Inc, New York, NY USA
[6] NYU, Ctr Hlth Sci, New York, NY USA
来源：
CIRCULATION | 2006年 / 114卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：713 / 714
页数：2
相关论文
共 6 条
  • [1] Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)
    Frey, Paul
    Waters, David D.
    DeMicco, David A.
    Breazna, Andrei
    Samuels, Larry
    Pipe, Andrew
    Wun, Chuan-Chuan
    Benowitz, Neal L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (02): : 145 - 150
  • [2] Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)
    Rocha, Evangelista
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2011, 30 (01) : 125 - 128
  • [3] Impact of Smoking on Cardiovascular Events in Patients With Established Coronary Disease Receiving Contemporary Medical Therapy: a Post Hoc Analysis of the Treating to New Targets (TNT) & the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Trials
    Frey, Paul F.
    Waters, David D.
    DeMicco, David A.
    Breazna, Andrei
    Samuels, Larry
    Pipe, Andrew L.
    Benowitz, Neal L.
    CIRCULATION, 2010, 122 (21)
  • [4] High HDL-C and CHD risk in statin-treated CHD patients: Analysis of incremental decrease in endpoints through aggressive lipid-lowering (IDEAL) trial
    Holme, I.
    Kastelein, J. J. P.
    Faergeman, O.
    Larsen, M. L.
    Lindahl, C.
    Olsson, A. G.
    Tikkanen, M. J.
    Cater, N. B.
    Pedersen, T. R.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 227 - 227
  • [5] Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease
    Faergeman, Ole
    Holme, Ingar
    Fayyad, Rana
    Bhatia, Sonal
    Grundy, Scott M.
    Kastelein, John J. P.
    LaRosa, John C.
    Larsen, Mogens Lytken
    Lindahl, Christina
    Olsson, Anders G.
    Tikkanen, Matti J.
    Waters, David D.
    Pedersen, Terje R.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (04): : 459 - 463
  • [6] The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies
    Arsenault, Benoit J.
    Boekholdt, S. Matthijs
    Hovingh, G. Kees
    Hyde, Craig L.
    DeMicco, David A.
    Chatterjee, Aurobindo
    Barter, Philip
    Deedwania, Prakash
    Waters, David D.
    LaRosa, John C.
    Pedersen, Terje R.
    Kastelein, John J. P.
    CIRCULATION-CARDIOVASCULAR GENETICS, 2012, 5 (01) : 51 - 57
1